THE SIMULTANEOUS QUANTIFICATION OF RIFAMPICIN AND ISONIAZID IN PATIENTS WITH TUBERCULOSIS APPLIED TO VOLUMETRIC ABSORPTIVE MICROSAMPLING DEVICES USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

HEMA NOVITA RENDATI; YAHDIANA HARAHAP; RAHMAYANTI

doi:10.22159/ijap.2024v16i1.49108

Authors

HEMA NOVITA RENDATI Faculty of Pharmacy, University of Indonesia, Depok, West Java, Indonesia https://orcid.org/0009-0002-9336-2846
YAHDIANA HARAHAP Faculty of Pharmacy, University of Indonesia, Depok, West Java, Indonesia. Faculty of Military Pharmacy, Republic of Indonesia Defense University, Bogor, Indonesia https://orcid.org/0000-0002-7217-7900
RAHMAYANTI Dr. Chasbullah Abdulmadjid Hospital, Bekasi, West Java, Indonesia

DOI:

https://doi.org/10.22159/ijap.2024v16i1.49108

Keywords:

Isoniazid, Rifampicin, TDM, Tuberculosis, VAMS

Abstract

Objective: Rifampicin and isoniazid are the main tuberculosis treatment regimens requiring blood level measurement to optimize the treatment process. This study aims to analyze rifampicin and isoniazid quantitatively in volumetric absorptive microsampling (VAMS) prepared from a small volume of TB patients using HPLC.

Methods: Analytes on the VAMS tip were extracted using 1000 ml of acetonitrile containing 10 µg/ml of cilostazol as an internal standard. Analytical separation was performed on the C-18 column at 40 ℃ with a mobile phase mixture of 50 mmol ammonium acetate buffer pH 5.0-acetonitrile-methanol (40:30:30), flow rate 0.5 ml/min. The analysis was carried out with the calibration curve over a range of 1.0–30 µg/ml for rifampicin and 0.4-20 µg/ml for isoniazid.

Results: Analyte analysis in 21 patients showed that the measured value of rifampicin was 3.39–16.77 µg/ml, and isoniazid was 2.63–10.43 µg/ml at 2 h post-dose. 52.38% of patients had low blood concentrations in at least one of the drugs, 28.57% of the patients were in the therapeutic range, and 23.81% had a high blood concentration of isoniazid alone.

Conclusion: The concentration of rifampicin and isoniazid in 21 tuberculosis patients varied. Dose adjustment is needed because most patients had low blood concentrations of one of the drugs, and a limited number had a high blood isoniazid concentration alone. Only some patients simultaneously had plasma concentrations within the target range of the drugs. This method was valid and reliably utilized for therapeutic drug monitoring of antituberculosis.

Downloads

Download data is not yet available.

References

Global tuberculosis report. World Health Organization; 2022. Available from: https://www.who.int/publications/i/item/9789240061729. [Last accessed on 01 Jul 2023]

Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P. Global tuberculosis report 2020–reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021 Dec;113Suppl 1:S7-S12. doi: 10.1016/j.ijid.2021.02.107, PMID 33716195.

Ramachandran G, Chandrasekaran P, Gaikwad S, Agibothu Kupparam HK, Thiruvengadam K, Gupte N. Subtherapeutic rifampicin concentration is associated with unfavorable tuberculosis treatment outcomes. Clin Infect Dis. 2020 Mar;70(7):1463-70. doi: 10.1093/cid/ciz380, PMID 31075166.

Mukonzo JK, Kengo A, Kutesa B, Nanzigu S, Pohanka A, McHugh TD. Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients. Trans R Soc Trop Med Hyg. 2020 Feb;114(2):107-14. doi: 10.1093/trstmh/trz108, PMID 31789383.

Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI. Serum levels of antituberculosis drugs and their effect on tuberculosis treatment outcome. Antimicrob Agents Chemother. 2016;60(1):92-8. doi: 10.1128/AAC.00693-15, PMID 26459901.

Londhe V, Rajadhyaksha M. Opportunities and obstacles for microsampling techniques in bioanalysis: special focus on DBS and VAMS. J Pharm Biomed Anal. 2020 Apr;182:113102. doi: 10.1016/j.jpba.2020.113102, PMID 32014628.

Krützmann ME, Martini RR, de Souza Guterres F, Kohlrausch R, Wagner SC, Mattevi VS. Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: method development and clinical application in patients with chronic myeloid leukemia. J Pharm Biomed Anal. 2023 Jan;222:115108. doi: 10.1016/j.jpba.2022.115108, PMID 36279845.

Marasca C, Mandrioli R, Sardella R, Vovk T, Armirotti A, Cavalli A. Dried volumetric microsampling approaches for the therapeutic drug monitoring of psychiatric patients undergoing clozapine treatment. Front Psychiatry. 2022 Jun;13:794609. doi: 10.3389/fpsyt.2022.794609, PMID 35722565.

Gao L, Smith N, Kaushik D, Milner S, Kong R. Validation and application of volumetric absorptive microsampling (VAMS) dried blood method for phenylalanine measurement in patients with phenylketonuria. Clin Biochem. 2023 Jun;116:65-74. doi: 10.1016/j.clinbiochem.2023.03.012, PMID 37001750.

Luyen LT, Hung TM, Huyen LT, Tuan LA, Huong DTL, Van Duc H. Simultaneous determination of pyrazinamide, rifampicin, ethambutol, isoniazid and acetyl isoniazid in human plasma by LC-MS/MS method. J App Pharm Sci. 2018 Sep;8(9):61-73. doi: 10.7324/JAPS.2018.8910.

Prahl JB, Lundqvist M, Bahl JM, Johansen IS, Andersen AB, Frimodt Møller N. Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry. APMIS. 2016 Nov;124(11):1004-15. doi: 10.1111/apm.12590, PMID 27546025.

Zuma P, Joubert A, van der Merwe M, Norman J, Waitt C, Court R. Validation and application of a quantitative LC-MS/MS assay for the analysis of first-line anti-tuberculosis drugs, rifabutin and their metabolites in human breast milk. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Nov;1211:123489. doi: 10.1016/j.jchromb.2022.123489, PMID 36215877.

US Food and Drug Administration. Guidance for industry bioanalytical method validation. Rockville: US FDA; 2018.

Puspitasari AW, Yunaz SR, Nadhilah L. Identification of drug-related problems in adults with tuberculosis at the Tebet subdistrict health center from Jul to Dec 2018. Int J App Pharm. 2020 Mar;12(1):74-7. doi: 10.22159/ijap.2020.v12s1.FF010.

Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014 Jun;74(8):839-54. doi: 10.1007/s40265-014-0222-8, PMID 24846578.

Widhiartini IAA, Wirasuta MAG, Sukrama DM, Rai IBN. Therapeutic drug monitoring of rifampicin, isoniazid, and pyrazinamide in newly-diagnosed pulmonary tuberculosis outpatients in Denpasar area. Bali Med J. 2019 Apr;8(1):107-13. doi: 10.15562/bmj.v8i1.1304.

Sileshi T, Telele NF, Burkley V, Makonnen E, Aklillu E. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in Ethiopian tuberculosis patients. Sci Rep. 2023;13(1):11438. doi: 10.1038/s41598-023-38716-3, PMID 37454203.

Setiawan SI, Ascobat P. Adverse reactions to first-line antituberculosis drugs as a risk factor of pulmonary tuberculosis treatment default in Jakarta, Indonesia. Int J Appl Pharm. 2019 Dec;11(6):80-33. doi: 10.22159/ijap.2019.v11s6.33551.

Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h postdose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013 Dec;17(12):1602-6. doi: 10.5588/ijtld.13.0019, PMID 24200276.

Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis. 2013 Feb;17(2):221-4. doi: 10.5588/ijtld.12.0279, PMID 23317957.

Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E. Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. Am J Respir Crit Care Med. 2018 Nov;198(9):1208-19. doi: 10.1164/rccm.201711-2333OC, PMID 29877726.

Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2013 Aug;57(8):3614-9. doi: 10.1128/AAC.02468-12, PMID 23689725.

Allanson AL, Cotton MM, Tettey JN, Boyter AC. Determination of rifampicin in human plasma and blood spots by high-performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal. 2007 Aug;44(4):963-9. doi: 10.1016/j.jpba.2007.04.007, PMID 17531423.

Vu DH, Koster RA, Bolhuis MS, Greijdanus B, Altena RV, Nguyen DH. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta. 2014 Apr;121:9-17. doi: 10.1016/j.talanta.2013.12.043, PMID 24607103.